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Abstract
Background—A number of genetic variants have been discovered by recent genome-wide
association studies for their associations with clinical coronary heart disease (CHD). However, it
is unclear whether these variants are also associated with the development of CHD as measured by
subclinical atherosclerosis phenotypes, ankle brachial index (ABI), carotid artery intima-media
thickness (cIMT) and carotid plaque.
Methods—Ten CHD risk single nucleotide polymorphisms (SNPs) were genotyped in
individuals of European American (EA), African American (AA), American Indian (AI), and
Mexican American (MA) ancestry in the Population Architecture using Genomics and
Epidemiology (PAGE) study. In each individual study, we performed linear or logistic regression
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to examine population-specific associations between SNPs and ABI, common and internal cIMT,
and plaque. The results from individual studies were meta-analyzed using a fixed effect inverse
variance weighted model.
Results—None of the ten SNPs was significantly associated with ABI and common or internal
cIMT, after Bonferroni correction. In the sample of 13,337 EA, 3,809 AA, and 5,353 AI
individuals with carotid plaque measurement, the GCKR SNP rs780094 was significantly
associated with the presence of plaque in AI only (OR = 1.32, 95% confidence interval: 1.17, 1.49,
P = 1.08 × 10−5), but not in the other populations (P = 0.90 in EA and P = 0.99 in AA). A 9p21
region SNP, rs1333049, was nominally associated with plaque in EA (OR = 1.07, P = 0.02) and in
AI (OR = 1.10, P = 0.05).
Conclusions—We identified a significant association between rs780094 and plaque in AI
populations, which needs to be replicated in future studies. There was little evidence that the index
CHD risk variants identified through genome-wide association studies in EA influence the
development of CHD through subclinical atherosclerosis as assessed by cIMT and ABI across
ancestries.
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Introduction
Coronary heart disease (CHD) is the leading cause of death and a major health burden
worldwide1. Subclinical atherosclerosis phenotypes, including carotid artery intima-media
thickness (cIMT), carotid plaque, and resting ankle-brachial index (ABI), reflect the degree
of atherosclerosis in coronary arteries and peripheral arteries. The associations between
cIMT and plaque and the subsequent development of incident CHD, ischemic stroke, and
heart failure have been well established in multiple epidemiologic studies2–8. ABI is an
assessment of the patency of the lower extremity arteries as an indication of the presence of
peripheral artery disease, and has also been associated with multiple clinical cardiovascular
outcomes9–11.
Recent genome-wide association studies (GWAS), mostly conducted in populations of
European ancestry, have identified a number of single nucleotide polymorphisms (SNPs)
associated with CHD12–18. Particularly, SNPs in the chromosome 9p21 region (e.g.
rs1333049) have been consistently associated with clinical CHD and related conditions in
multiple studies12–18. However, in many cases, the biologic mechanisms underlying these
associations remain unknown. Determination of whether these variants are associated with
intermediate cardiovascular phenotypes, such as subclinical atherosclerosis, may help
further our understanding of pathogenic mechanisms for CHD. To date, there have been six
GWAS of subclinical atherosclerosis in EA18–23. Two studies identified several genome-
wide significant loci for common cIMT and plaque which have not been associated with
CHD previously20. A GWAS study of ABI identified associations with rs10757269, a SNP
in high LD with rs1333049 (r2 > 0.8) at the 9p21 region.21
Several other smaller studies that have examined the associations between CHD risk SNPs
and subclinical atherosclerosis have shown mixed results.22–26. Two candidate gene studies
in European descent individuals reported associations of rs1333049 with prevalent (P =
0.004 to 0.006 in different samples) and incident (P < 0.0001) carotid plaque24, and ABI (P
= 1.3 × 10−4)25. However, other studies in European populations (sample sizes ranging from
854 to 2277) showed a lack of association between CHD risk SNPs and common cIMT26–28.
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Overall, most studies were conducted in populations of European descent, had relatively
small sample sizes, and not always analyzed carotid artery plaque burden. Therefore, we
conducted the current study, as a part of the Population Architecture using Genomics and
Epidemiology (PAGE) Study29, to investigate whether genetic variants reported to be
associated with CHD in individuals of European ancestry are associated with ABI, common
and internal cIMT, and carotid artery plaque in individuals of European American (EA), as
well as African American (AA), American Indian (AI) and Mexican American (MA).
Methods and Materials
Study population
Data from five population-based studies in the PAGE study were included: the
Atherosclerosis Risk In Communities (ARIC) Study30, the Cardiovascular Health Study
(CHS)31, the Strong Heart Study (SHS)32, the Strong Heart Family Study (SHFS)33, and the
National Health and Nutrition Examination Surveys (NHANES 1999–2002), the latter of
which is accessed by Epidemiologic Architecture for Genes Linked to Environment
(EAGLE) investigators34. Study designs of these five studies are summarized in
Supplemental Table 1. Participants in all five studies provided written informed consents.
All studies were approved by the institutional review boards of the participating institutions.
Participants were excluded if they did not self-identify themselves as one of the following
four populations: EA, AA, AI, or MA, or if they did not consent to genetic research.
Participants without genotype information or missing information on phenotypes were
further excluded from analyses. Participants with ABI > 1.4 were excluded from the
analyses of ABI. Total sample sizes for analyses of ABI were 15,113 in EA, 4,472 in AA,
1,984 in AI and 944 in MA. The sample sizes for analyses of cIMT were 13,002 in EA,
3,615 in AA and 5,315 in AI. The sample sizes for analyses of plaque were 13,330 in EA,
3,807 in AA and 5,318 in AI.
SNP genotyping
Using GWAS results that were published as of January 2009, we selected the following ten
candidate SNPs: rs2144300 (GALNT2)16, rs599839 (CELSR2/PSRC1/SORT1)14, rs780094
(GCKR)16, rs499818 (6p24.1)18, rs10757278 (9p21)13, rs1333049 (9p21)12, 14, rs2383206
(9p21)17, rs2383207 (9p21)13, rs17228212 (SMAD3)14, and rs2549513 (16q23.1)18.
For the majority of the SNPs, the CALiCo Core Genotyping Laboratory at Human Genetics
Center at University of Texas (Houston, TX) genotyped samples from ARIC, CHS, SHS and
SHFS using Taqman assays (Applied Biosystems by Life Technology, Carlsbad, CA). For
some of the SNPs in both the ARIC study and the CHS, GWAS data (Affymetrix 6.0 for
ARIC and Illumina Human 370CNV BeadChip for CHS)35 were used: rs2549513 in ARIC
and rs2383207, rs2549513, rs780094 and rs499818 in CHS were genotyped in their
respective GWAS arrays. In addition, rs2383207 and rs499818 in ARIC were derived from
imputation of the GWAS panel with around 2.5 million SNPs using the phase II HapMap
European CEU reference panel. In EAGLE, NHANES 1999–2002 genotyping was
performed by the Vanderbilt University DNA Resources Core using the Life Technologies
OpenArray (rs599839) and the Illumina BeadXpress (rs2383206 and rs17228212).
Genotyping in EAGLE was also performed in the laboratory of Dr. Jonathan Haines for
rs2144300, rs780094, rs10757278, and rs2383207 using the iPLEX® Gold assay
(Sequenom®, Inc, San Diego, CA). Quality control assessments included sample call rates
(> 90%), concordance of blinded replicates (> 98%) and deviation from Hardy-Weinberg
equilibrium among controls within self-reported racial groups (P ≥ 0.01), except for
rs10757278 in ARIC AA (excess in heterozygotes, P = 0.001). For imputed SNPs, the
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posterior probability of the most likely genotype (r2) was 0.97 for rs2383207 and 0.91 for
rs499818.
Outcome measurement—Outcomes were taken from Visit 1 of the ARIC study (1987–
89), Year 5 of the CHS (1994–95), Phase III of the SHS (1998–99), Phase IV of the SHFS
(2001–03) and NHANES 1999–2002. All studies defined ABI as the ratio of the mean
systolic blood pressure of both ankles to the brachial systolic blood pressure of the right
arm, except for the ARIC study, where the systolic blood pressure from one randomly
selected ankle was used. In NHANES, only adults aged 40 years and older at the study
interview were measured for ABI.
In all studies except for NHANES, cIMT and plaque were measured by trained and certified
sonographers using standardized protocols and equipment. In NHANES, cIMT and plaque
were not measured. The study protocols and descriptive and quality control statistics have
been previously published36–40. All studies used high-resolution B-mode real-time
ultrasound to bilaterally assess the presence of discrete plaque and cIMT in the common,
bifurcation and internal carotid artery except for the SHS and the SHFS, where internal
cIMT was not measured. At each arterial segment, multiple measurements of the far wall of
the cIMT were taken, and the derived mean cIMT of multiple measurements of left and right
sides was used in the current analysis. Each study considered the presence of plaques
differently when measuring cIMT. In the ARIC study, cIMT was measured regardless of the
presence of plaque. In the CHS, cIMT measurement was centered at the site of plaque. In the
SHS and the SHFS, cIMT was never obtained at the level of a discrete plaque. Each study
also defined carotid plaque differently. In the SHS and the SHFS, plaque was defined as
focal thickening of > 50% of the surrounding wall at any available arterial segments. In the
ARIC study, plaque was defined if two of the following three criteria were met: 1) abnormal
arterial wall thickness (defined as cIMT > 1.5mm); 2) abnormal shape (protrusion into the
lumen, loss of alignment with adjacent arterial wall boundary); 3) abnormal wall texture
(brighter echoes than adjacent boundaries). In the CHS, plaque was defined as stenosis
degree less than 25% because most plaques are non-obstructive36, 40, 41. All phenotypes
were carefully harmonized across studies for the purpose of meta-analysis29.
Statistical Methods
All study-specific association analyses were stratified by self-reported race/ethnicity (EA,
AA, AI and MA). Natural log transformation of cIMT measurements was performed. An
additive genetic model was assumed for all SNPs. The associations between SNPs and ABI,
common cIMT and internal cIMT were examined using multivariate linear regression
adjusting for sex, age (at baseline), and center if applicable. Logistic regression was used for
the analyses of plaque adjusting for sex, age (at baseline), and center if applicable. In the
SHFS, a variance components-based biometrical model with random effects was used to
account for kinship42. The population-specific beta coefficients or log odds ratios (ORs)
were meta-analyzed across studies using a fixed effect inverse variance weighted model to
obtain joint estimates. To reduce type I error in results of associations, the Bonferroni
correction was applied (alpha = 0.05/10 = 0.005).
Exploratory analyses were performed to examine potential effect modification by CHD risk
factors (e.g. type 2 diabetes, hypertension). In each study, we stratified the population-
specific samples into subgroups (type 2 diabetes: yes/no; hypertension: yes/no) and further
evaluated the heterogeneity of associations of SNPs with outcomes of interest between
subgroups. We used Cochran’s Q test to assess heterogeneity across studies and across
subgroups43. A Q statistic with P for heterogeneity (Phet) < 0.05 indicated significant
heterogeneity.
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Besides the simple model with adjustment of sex, age and center (if applicable), two sets of
sensitivity analyses were performed: 1) in all five studies, a complex model was performed
adjusting for sex, age, center if applicable, body mass index (BMI), smoking (current/
former/never smoker), hypertension, type 2 diabetes, low density lipoprotein (LDL)
cholesterol, high density lipoprotein (HDL) cholesterol and triglyceride levels. All
covariates were from the visit when the outcomes were derived; 2) to examine the potential
confounding effect of population stratification, in the ARIC study, we adjusted for principal
components (PCs) that were derived from GWAS data44 and were associated with the
outcomes at alpha = 0.05. In the SHFS, to test for population stratification, we compared the
likelihood of a model in which the association parameters, βb (between family genotype
score) and βw (within family genotype score), were estimated, to the likelihood of a model
in which they were constrained to be equal, as would be the case in the absence of
population stratification45, 46. Analyses were performed with either Stata 11 (College
Station, Texas) or SAS V9.2 (Cary, NC) in all studies except SHFS. Analyses in the SHFS
were implemented in the SOLAR (Sequential Oligogenic Linkage Analysis Routines, San
Antonio, Texas) software package (version 4.4)46, 47. Meta-analyses were conducted using
“metan” module in Stata 11. Aggregate statistics related to this work will be available via
dbGaP as part of the PAGE study.
We performed power calculations assuming an additive genetic effect, risk allele
frequencies of the target populations, a two-sided alpha = 0.005, using continuous phenotype
distributions or population baseline prevalence from the target populations (Quanto V.
1.2.4)48.
Results
Baseline characteristics of the study participants by population are summarized in Table 1.
The average ABIs in EA, AA, AI, and MA were 1.11, 1.09, 1.12 and 1.11, respectively. In
the analyses of cIMT and plaque, because of the inclusion of the SHFS, the AI study
population was larger (n = 5,353) and younger (mean age = 50.8 years) compared to the
samples used for the ABI analyses (n = 1,984, mean age = 63.3 years). The mean of
common cIMT was very similar in the EA (0.77mm) and AA (0.78mm) populations, both of
which were higher than the mean of common cIMT in AI (0.70mm). On the other hand, the
prevalence of plaque was much higher in AI (45.0%), compared to 32.9% in EA and 31.6%
in AA.
Associations between each of the ten SNPs and subclinical atherosclerosis phenotypes from
the simple model are presented in Figure 1 and Tables 2–5. In meta-analyses, there was no
evidence for heterogeneity of associations across studies (Phet > 0.05, Tables 2–5). For ABI,
common and internal cIMT, there was no significant association of any of the ten SNPs at
the 0.005 level. However, there was a significant association between rs780094 (minor allele
frequency = 0.20) and the presence of plaque in the AI population (age-, sex-adjusted OR =
1.32, 95% confidence interval (CI): 1.17, 1.49, P = 1.08 × 10−5). The association remained
significant in the complex model with adjustment of age, sex, BMI, smoking, hypertension,
type 2 diabetes, LDL cholesterol, HDL cholesterol and triglyceride levels (OR = 1.34, 95%
CI: 1.18, 1.53, P = 6.97 × 10−6). In addition, the associations between rs780094 and plaque
were consistent across the three study centers of the SHS and the three centers of the SHFS
(test for heterogeneity: Phet = 0.45) (Figure 2). However, SNP rs780094 was not associated
with plaque in the other populations (OR = 0.99, P = 0.90 in EA; OR = 1.00, P = 0.99 in
AA).
Since rs1333049 was previously associated with ABI and plaque in EA24, 25, we specifically
examined these associations in a larger number of multiethnic individuals; however, no
Zhang et al. Page 5













association was observed with ABI in any of our populations (beta coefficient (β) =
−0.0014, P = 0.37 in EA; β = −0.0013, P = 0.73 in AA; β = 0.0026, P = 0.54 in AI; β =
−0.0050, P = 0.39 in MA). In EA and AI, the association between rs1333049 and plaque
appeared to be direction-consistent with the original report12 (OR = 1.07, P = 0.02 in EA;
OR = 1.10, P = 0.05 in AI), but the results were not statistically significant after Bonferroni
correction. In the AA population, rs1333049 was not associated with plaque (OR = 0.90, P =
0.08).
The exploratory analyses examining potential heterogeneity of gene-phenotype associations
by hypertension and by type 2 diabetes status showed that very few SNPs had Phet < 0.05
between subgroups (Supplemental Tables 2–7). Moreover, none of these heterogeneous
associations were observed across all populations.
In the sensitivity analysis, results from the complex model remained unchanged compare to
the simple model. In the ARIC study, the association results obtained from models with and
without adjusting for PCs did not differ and the causal inference was not changed in EA and
AA. In the SHFS, as implemented in SOLAR, the tests for population stratification for
rs780094 were not significant (P > 0.05)49.
Discussion
In populations of EA, AA, AI and MA ancestry from the PAGE study, we found little
evidence for the associations between ten candidate SNPs for clinical CHD and measures of
subclinical atherosclerosis, including ABI, common cIMT, and internal cIMT. The GCKR
SNP rs780094 was significantly associated with presence of plaque in AI. Each copy of the
A allele in rs780094 was associated with a 1.32-fold increase in odds of carotid plaque (95%
CI: 1.17, 1.49, P = 1.08 × 10−5). This finding will need to be replicated in additional samples
of AIs and other populations.
These findings are important for several reasons. First, our analysis consisted of a large
sample of EA from population-based settings than previous candidate gene studies that
examined the association between CHD risk SNPs and subclinical atherosclerosis24–28. With
our samples, we had 80% power to detect a β of 0.007 or larger in the analysis of ABI, a β
of 0.008 or larger in the analysis of cIMT, and an OR of 1.12 or larger in the analysis of
plaque in the EA population. More importantly, this is the first investigation of these
candidate SNPs with subclinical atherosclerosis phenotypes in large and reasonably powered
samples of major U.S. populations other than European descendents: AA, AI and MA. In the
AA population, we had 80% power to detect a β of 0.016 for ABI, a β of 0.019 for cIMT,
and an OR of 1.31 for plaque. In the AI population, we had 80% power to detect a β of 0.02
for ABI, a β of 0.014 for cIMT, and an OR of 1.19 for plaque. In the MA population, we had
80% power to detect a β of 0.026 in the ABI analysis. Lastly, we were able to assess
associations between CHD risk SNPs and carotid plaque, which is a more specific
atherosclerosis phenotype and a better predictor of clinical CHD than cIMT50, but has not
been frequently examined in previous studies27, 28. We found no association between CHD
risk SNPs and ABI, common and internal cIMTs. SNP rs780094 was highly significantly
associated with plaque in AI, but not in EA and AA populations. Though previous studies
suggested that the association between 9p21 locus rs1333049 and ABI and plaque may
exist24, 25, we were not able to replicate these associations, likely due to differences in study
populations and designs.
Our most significant finding was the association between the A allele in rs780094 and the
presence of plaque in AI (OR = 1.32, 95% CI: 1.17, 1.49, P = 1.08 × 10−5). However, this
association was not observed in either the EA or AA populations despite the fact that this
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study had at least 90% power to detect an OR of 1.32 in our samples. SNP rs780094 is
located in an intron of Glucokinase Regulatory Protein gene (GCKR, OMIM: 600842,
2p23.3) and has been associated with fasting glucose, triglycerides, LDL cholesterol, C-
reactive protein, serum uric acid, serum phospholipid and metabolic traits16,51–56. In EA and
Asian, rs780094 is in tight LD with rs1260326 (r2 = 0.93 and 0.90, respectively), which
encodes a common missense variant in GCKR. In AA there is some LD among these SNPs
(r2 = 0.47), but the LD in AI is unknown. In both ARIC and CHS, the association between
the risk allele (A) of rs780094 and higher levels of fasting serum triacylglycerol, total
cholesterol, and serum uric acid but lower levels of fasting blood glucose in EA populations
were previously reported57, 56, 58 and consistent with other studies. However, despite these
associations, this SNP was not associated with subclinical CHD outcomes in these two
studies. In our sample of AI, this association was independent of lipid levels and type 2
diabetes (OR = 1.34, 95% CI: 1.18, 1.53, P = 6.97 × 10−6) after adjusting for sex, age,
centers, BMI, smoking, hypertension, type 2 diabetes, LDL cholesterol, HDL cholesterol
and triglyceride levels. There have been no previous reports of the association of rs780094
with plaque, but it has been shown to be associated with common cIMT in 455 Caucasians
with metabolic syndrome (P < 0.05)59. However, we were not able to replicate this
association in our samples of EA, which may be due to differences in the study populations
since we have population-based individuals, while the previous study focused on a small
number of individuals with metabolic syndrome. On the other hand, the association between
rs780094 and plaque may be a false positive. However, family studies are robust to
population stratification. In our prior evaluation of population stratification in the SHFS
using quantitative trait linkage disequilibrium tests49, we found no evidence population
substructure for this SNP. The A allele is more common in the EA population (40% in EA
vs 20% in AI), whereas the prevalence of plaque was lower (32.9% in EA vs 45.0% in AI).
Similarly, in the AA, the frequency of the A allele in rs780094 is slightly lower (0.18 in AA
vs 0.20 in AI), whereas the prevalence of plaque is much lower in AA (31.6% in AA vs
45.0% in AI). Given that the A allele is associated with an increased risk of plaque, it does
not appear that confounding by EA or AA admixture in the AI population leads to the
observed association in AI. In summary, the association between rs780094 and plaque in the
AI population needs to be replicated in future studies.
Another suggestive finding is the association between rs1333049 on chromosome 9p21 and
prevalence of plaque. SNPs in the chromosome 9p21 region (close to the CDKN2A/2B
gene) have been consistently associated with clinical CHD, incident CHD, heart failure,
myocardial infarction, coronary artery calcification, ischemic stroke and abdominal aortic
aneurysm in populations of European ancestry12–18. However, associations between these
SNPs and subclinical atherosclerosis phenotypes have been conflicting22–26. While some
studies reported associations of rs1333049 with plaque and ABI24, 25, three other candidate
studies failed to detect associations between 9p21 SNPs (rs1333049, rs7044859, rs496892,
rs7865618, rs4977574) and cIMT26–28. In the current analyses, we observed direction-
consistent associations between the C allele in rs1333049 and decreased ABI, increased
cIMT and increased risk of plaque in our EA population, as in previous findings with
clinical CHD and with subclinical atherosclerosis. In a recent meta-analysis of 21 GWAS,
rs10757269, in high LD with rs1333049 (r2 = 0.87 in CEU from HapMap III), was
associated with ABI (β = −0.006, P = 2.46 × 10−8)21. In a previous PAGE analysis60 of
6,626 individuals with CHD, rs10757278, in high LD with rs1333049 (r2 = 0.9 in EA) in the
9p21 region, was significantly associated with incident CHD (hazard ratio = 1.19, P = 4.7 ×
10−41)60. The lack of significant associations in our study is likely due to the modest effect
size (β = −0.0014 in ABI analyses) and relatively small sample size compared to previous
studies.
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There are several aspects of the study that strengthened our findings. First, the current study
examined associations between SNPs for clinical CHD and subclinical atherosclerosis
intermediate phenotypes, which have been thought to be a way to increase statistical power
for finding genes for complex traits61. The “upstream” intermediate phenotypes (e.g.
plaque), which are more proximal to the genes on the pathogenic pathway, should be more
strongly associated with the genetic variants than the “downstream” clinical traits (CHD)62.
Such association studies may theoretically elucidate how these CHD genetic variants act on
the pathogenesis of CHD through the development and progression of atherosclerosis.
Second, our analyses included large studies from multiple racial/ethnic backgrounds with
well-characterized and harmonized phenotypes. Despite the lack of power to detect the
modest associations with ABI, common cIMT and internal cIMT, we have identified a
highly significant association in the analyses of plaque.
We also note the limitations of our study. Although phenotypes were carefully harmonized,
due to the complexity of these phenotypes and differences in study protocols, some
unresolved heterogeneity in the measurement of phenotypes may still exist limiting our
power to detect associations. Second, two imputed SNPs with relatively high imputation
scores (r2 is 0.97 for rs2383207 and 0.91 for rs499818) were used in some of our analyses.
However, similar inferences were made when these genotypes were not included in the
analyses. Lastly, in the present study, we simply evaluated the published index variant
identified from previous GWASs, which were primarily found in populations of European
ancestry; therefore, differences in linkage disequilibrium between the available tested SNP
and the “causative” variant in different populations were not accounted for in our study and
may have obscure true associations in these regions.
In conclusion, using the diverse populations from the PAGE study, we found that rs780094
(GCKR) was significantly associated with the presence of carotid plaque in American Indian
populations. This association appears to be population-specific and will need to be replicated
in future studies. In addition, there was little evidence that CHD susceptibility variants
identified through GWAS influence the development of CHD through subclinical
atherosclerosis as assessed by cIMT and ABI.
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• We examine the associations between CAD risk SNPs and subclinical
atherosclerosis
• We include large samples of African Americans, Mexican Americans, and
American Indians
• SNP rs780094 is significantly associated with plaque in American Indians
• Lack of association between CAD risk SNPs with ABI and cIMT
Zhang et al. Page 13














Associations of Single Nucleotide Polymorphisms with Ankle Brachial Index, Plaque,
Common Carotid and Internal Carotid Artery Intima-media Thickness (IMT) in the
Population Architecture Using Genetics and Epidemiology (PAGE) study, by Populations.
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Population- and study-specific and pooled associations between rs780094 and plaque in the
Population Architecture Using Genetics and Epidemiology (PAGE) study, by populations.
Odd ratio and 95% confidence intervals (95%CI) are obtained from logistic regression
model adjusting for sex, age and center if applicable. I2 and Phet are obtained from
Cochran’s Q test using a fixed effect model. The size of each square is proportional to the
percent weight that each population-, study-specific group contributed in the overall
association. Diamond represents the pooled odds ratio for each population. Bars represent
the 95% confidence intervals for the odds ratios.
Abbreviations: ARIC, Atherosclerosis Risk in Communities; AZ, Arizona; CHS,
Cardiovascular Health Study; NHANES, National Health and Nutrition Examination
Survey; OK, Oklahoma; SD, South Dakota; SHFS, Strong Heart Family Study; SHS, Strong
Heart Study.
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Table 1
Characteristics of Participants in the Analysis of Ankle Brachial Index and Intima-media thickness/Plaque in











N = 15,113 N = 4,472 N = 1,984 N = 944
Ankle brachial index, mg/dL 1.11 (0.14) 1.09 (0.14) 1.12 (0.14) 1.11 (0.13)
Age, years 60.5 (6.3) 57.3 (6.2) 63.3 (7.8) 57.2 (11.9)
Female, % 53.6 60.4 64.4 48.3
Body-mass index, kg/m2 27.0 (4.8) 29.4 (5.9) 31.2 (6.6) 29.0 (5.3)
Smoking status, %
   Current 20.3 26.8 29.1 20.0
   Former 38.1 26.4 34.5 33.1
   Never 41.6 46.8 36.3 46.9
Type 2 diabetes, % 10.1 20.0 47.1 15.5
Hypertension, % 39.8 60.5 54.4 41.6
LDL Cholesterol, mg/dL 132.1 (37.2) 134.2 (41.5) 118.0 (32.8) 126.8 (32.6)
HDL Cholesterol, mg/dL 51.3 (16.4) 55.5 (17.4) 42.1 (13.4) 48.5 (13.8)
Triglycerides, mg/dL 144.8 (96.2) 114.8 (76.7) 154.8 (112.7) 186.9 (148.7)
Participant characteristics-Intima-media
thickness/plaque analysis#
N = 13,337 N = 3,809 N = 5,353 NA
Common Carotid IMT, mm 0.77 (0.16) 0.78 (0.16) 0.70 (0.16) NA
Internal Carotid IMT, mm 0.93 (0.32) 0.83 (0.23) NA NA
Prevalence of Plaque, % 32.9 31.6 45.0 NA
Age, years 60.2 (5.3) 57.5 (5.8) 50.8 (13.9) NA
Female, % 54.2 62.6 62.0 NA
Body-mass Index, kg/m2 26.9 (4.8) 29.3 (5.9) 32.0 (7.4) NA
Smoking status, % NA
   Current 20.2 26.0 32.4 NA
   Former 38.4 26.8 29.7 NA
   Never 41.5 47.2 37.9 NA
Type 2 diabetes, % 10.6 20.8 34.0 NA
Hypertension, % 37.9 60.3 43.0 NA
LDL Cholesterol, mg/dL 132.6 (37.2) 135.0 (42.4) 106.5 (30.5) NA
HDL Cholesterol, mg/dL 51.6 (16.4) 55.6 (17.4) 47.6 (14.3) NA
Triglycerides, mg/dL 141.0 (91.9) 113.9 (74.5) 161.3 (112.6) NA
Abbreviations: N/A, not applicable.
a
Data are mean (standard deviation).
b
Ankle Brachial Index was measured in participants of the ARIC study, CHS, NHANES 1999–2002, and SHS. Participants were excluded if they
did not self identify as any of above populations, or did not consent to genetic study, or missed Ankle Brachial Index measurement or ABI > 1.4.
SNP rs17228212 and rs2383206 were not genotyped in the CHS and SHS cohort component, so sample sizes for the analysis of these two SNPs
were 11,522 in EA, 3,714 in AA and 944 in MA. SNP rs2549513 and rs499818 were not genotyped in the NHANES 1999–2002 and SHS cohort
component, so sample sizes for the analysis of these two SNPs were 12,739 in EA and 3,776 in AA.
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c
Intima-media thickness and plaque were measured in participants of the ARIC study, CHS, SHS and SHFS. Participants were excluded if they did
not self identify as any of above populations, or did not consent to genetic study, or not measured for carotid sonogram. SNP rs2549513 and
rs499818 were not genotyped in the SHS, so sample sizes for the analysis of these two SNPs associated with IMT/plaque were 13,337 in EA and
3,809 in AA.
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